ClinicalTrials.gg
Active, not recruitingNCT04835428Updated May 8, 2026

STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures

An interventional study of Treatment Group: AGN1 LOEP SV Kit and Control Group: PMMA bone cement in Vertebral Compression Fracture, Compression Fracture and Vertebral Compression, sponsored by AgNovos Healthcare, LLC. Active, not recruiting at 12 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.

Read the detailed description

Four hundred and eight (408) eligible subjects at up to twenty-five (25) study sites will be randomized 1:1 for treatment using the AGN1 LOEP SV Kit (Intervention Group) or PMMA bone cement (Active Control Group).

  1. Intervention Group - receives vertebral augmentation of the target VCF(s) using the AGN1 LOEP SV Kit
  2. Active Control Group - receives vertebral augmentation of the target VCF(s) using either Stryker VertaPlex HV or Medtronic Kyphon HV-R.

Follow-up visits will be conducted at 7 days, 28 days, 3 months, 12 months and 24 months after the procedure.

02

Conditions studied

  • Vertebral Compression Fracture
  • Compression Fracture
  • Vertebral Compression

Browse trials for

Keywords

  • LOEP
  • AGN1
  • STAND
  • Local Osteo-Enhancement Procedure
03

In context

Fractures, Compression

50 studies on the registry are indexed under Fractures, Compression; 10 are open to participants now.

This study's planned enrollment of 408 is above the median of 73 across 32 interventional studies indexed under Fractures, Compression.

Browse Fractures, Compression studies →

Lead sponsor

AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female 50 years of age or older at the time of study treatment.
  2. Subject has one (1) or two (2) acute VCF(s). Note that subjects are eligible if they have an asymptomatic, healed VCF(s) at any non-target vertebral level.
  3. Each target VCF meets all of the following criteria:

    1. Due to diagnosed or presumed underlying osteoporosis
    2. T1 to L5 inclusively
    3. Target VCF-related pain ≤ 6 months at time of study treatment
  4. Each target VCF shows loss of height of the vertebral body ≤ 50% based on X-ray at baseline.
  5. Each target VCF is acute or persistent (not healed), as demonstrated on imaging, including T2-weighted, STIR MRI, bone scan or bone scan with SPECT/CT, serial radiographs, or other serial imaging demonstrating acuity.
  6. Focal tenderness to palpation of the spinal process of each target VCF on the physical exam correlates with imaging.
  7. Subject has failed conservative medical therapy (bed rest, observation, chiropractic care, orthotics, opioid and non-opioid analgesics, and/or physical therapy), defined as either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks of conservative care or a VAS back pain score of ≥ 50 mm after more than 6 weeks of conservative care.
  8. Subject has an Oswestry Disability Index (ODI) score of ≥ 30% at baseline.
  9. Subject is capable of giving written to participate in the study.
  10. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full length of the study has been documented

Exclusion criteria

Exclusion Criteria:

  1. At least one of the target VCF(s) is unstable, including split or burst fracture.
  2. Subject has a bleeding disorder.
  3. Subject has an active infection of the spine or surgical site.
  4. Subject has a bloodborne infection.
  5. At least one of the target VCFs is due to underlying or suspected tumor.
  6. At least one of the target VCFs is due to high-energy trauma.
  7. At least one of the target VCFs is due to osteonecrosis.
  8. At least one of the target VCFs has a local kyphotic angle of > 30 degrees, measured as the angle between the superior endplate and inferior endplate at the target VCF.
  9. Subject has had any prior surgical treatment at the target vertebral level or adjacent vertebral levels.
  10. The pedicle(s) in the target vertebral body appears unable to safely accommodate transpedicular access instrumentation.
  11. Subject has neurologic symptoms, deficits, or radiculopathy related to the target VCF(s).
  12. Subject has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated.
  13. Subject has pain, progressive weakness, or paralysis due to herniated nucleus pulposus or spinal stenosis.
  14. Subject has spondylolisthesis > Grade 1 at target vertebral body(ies).
  15. Subject requires daily opioid medication for pain not related to the target VCF(s).
  16. Subject has severe cardiopulmonary deficiencies.
  17. Subject has a (BMI) > 35.
  18. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
  19. Subject has a history of tuberculous spondylitis.
  20. Subject has a history of invasive within the last five (5) years, other than non-melanoma skin cancer. Subject is not excluded if they have a history of malignancy over 5 years ago treated with curative intent and without clinical signs or symptoms since then.
  21. Subject is on oral or parenteral immune-suppressive drugs.
  22. Subject has uncontrolled diabetes mellitus.
  23. Subject has severe renal insufficiency defined as an estimated (eGFR) \< 30 mL/min.
  24. Subject has a diagnosed calcium metabolism disorder.
  25. Subject has known allergies to calcium-based bone void fillers.
  26. Subject is pregnant or planning to become pregnant during participation in the study.
  27. In the judgment of the Investigator, the subject is not a good study candidate. (e.g. substance abuse or chemical dependency, inability to adhere to follow-up schedule, progression of the fracture between screening and the procedure visit).
  28. Subject is currently enrolled in another interventional clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Treatment with AGN1 LOEP SV Kit

    The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.

    Device: Treatment Group: AGN1 LOEP SV Kit

  • Active comparator
    Treatment with PMMA bone cement

    High viscosity PMMA bone cement will be used for vertebral augmentation.

    Device: Control Group: PMMA bone cement

Interventions

  • DeviceTreatment Group: AGN1 LOEP SV Kit

    The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.

  • DeviceControl Group: PMMA bone cement

    High viscosity PMMA bone cement will be used for vertebral augmentation.

06

What researchers measure

Primary outcomes

  1. Change in VCF-related Pain as measured by a 100 mm Visual Analogue Scale (VAS)

    Change in VCF-related pain by \> 20 mm from baseline as measured by a 100 mm Visual Analogue Scale (VAS) where 0mm is no pain, and 100mm is worst pain possible.

    Time frame: 24 months

  2. Change in function

    change of function from baseline as measured by the Oswestry Disability Index (ODI)

    Time frame: 24 months

  3. Radiographic evidence of implant resorption (Intervention Group only)

    change in resorption from procedure as assessed by independent radiographer

    Time frame: 24 months

  4. Radiographic evidence of bone formation (Intervention Group only)

    change in bone formation from procedure as assessed by independent radiographer

    Time frame: 24 months

  5. Adverse events

    Occurrence of device-related serious adverse events, device-related adverse events or serious adverse events categorized as failure or surgical intervention at the target level occurring post-treatment

    Time frame: 24 months

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2021
First posted
Apr 8, 2021
StartActual
May 31, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04835428
Lead sponsor
AgNovos Healthcare, LLC
Responsible party
Sponsor
First posted
Apr 8, 2021
Start date
May 31, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 8, 2026

Study contacts

Kern Singh
principal investigator · Midwest Orthopedics at Rush

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion